Highlights

  • Two patients at the highest CDH17 CAR-T dose recorded tumour shrinkage of 17% to 40%.
  • A fifth patient has been manufactured and is ready for dosing, while a sixth remains subject to funding.
  • The therapy received FDA Orphan Drug and Fast Track designations during 2026.
  • Trial progression continues alongside funding requirements and ongoing safety monitoring.

Chimeric Therapeutics Ltd (ASX:CHM) has reported encouraging early efficacy data from the highest dose cohort of its Phase 1/2 CDH17 CAR-T clinical trial, with measurable tumour shrinkage observed in two patients. The update represents another milestone for the clinical-stage biotechnology company as it advances its lead cell therapy program across gastrointestinal cancers. While the results provide additional clinical evidence supporting further development, the study remains in its early stages and future progress will depend on continued patient enrolment, funding availability and regulatory advancement.

Highest Dose Cohort Shows Early Clinical Activity

Chimeric announced that four patients have now received the highest planned dose of 450 million CDH17 CAR-T cells in its ongoing Phase 1/2 study.

According to the company, two of those patients recorded reductions in individual tumour lesions ranging from 17% to 40% under RECIST 1.1 assessment criteria. The same patients also maintained stable disease for approximately four and six months respectively.

The company confirmed that manufacturing has been completed for a fifth patient, who is ready for treatment. A sixth patient is expected to be enrolled later in 2026, although management noted that this remains dependent on securing additional funding.

The trial is evaluating CHM CDH17 in patients with relapsed or refractory gastrointestinal cancers who have previously received standard treatments.

Regulatory Support Continues to Build

Alongside the clinical update, Chimeric has secured two important regulatory designations from the US Food and Drug Administration during the past year.

The therapy received Orphan Drug Designation for gastric cancer in December 2025, followed by Fast Track Designation for gastroenteropancreatic neuroendocrine tumours in July 2026.

These designations are intended to support the development of therapies addressing serious diseases with limited treatment options. However, they do not represent marketing approval or guarantee future commercialisation.

The company continues advancing the clinical program while collecting additional efficacy and safety data across the remaining dose cohorts.

Pipeline Centres on Cell Therapy Programs

Chimeric Therapeutics is a clinical-stage biotechnology company focused on developing CAR-T and natural killer (NK) cell therapies for cancer treatment.

Its lead asset, CHM CDH17, targets the CDH17 protein expressed in several gastrointestinal cancers, including colorectal cancer, gastric cancer and gastroenteropancreatic neuroendocrine tumours.

Earlier updates from the study reported disease control across multiple patients treated at lower dose levels before escalation to the current highest dose cohort.

The company has also streamlined its broader development portfolio during 2026, placing greater emphasis on advancing the CDH17 program.

Funding Remains a Key Consideration

Despite the encouraging clinical data, Chimeric remains a pre-revenue biotechnology company that relies on external funding to continue clinical development.

The company previously completed a 1-for-100 share consolidation and has utilised placements and convertible note funding to support operations.

Management has acknowledged that completion of the highest-dose cohort will require additional funding, highlighting the importance of future capital management alongside clinical execution.

Upcoming milestones are expected to include further patient dosing, additional efficacy and safety updates, and continued engagement with regulators as the study progresses.

What Investors May Watch

Investors may monitor enrolment of the remaining Dose Level 3 patients, future clinical data releases, safety outcomes, funding initiatives, regulatory developments and progress towards later-stage clinical studies.

Risks

Chimeric Therapeutics remains exposed to clinical trial risk, regulatory uncertainty, funding requirements, shareholder dilution, patient recruitment challenges, manufacturing complexity and the possibility that early efficacy signals may not be replicated in larger studies.